Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 14 Dec 2021
Heterogeneity of treatment effect; estimating how the effects of interventions vary across individuals
14 December 2021 - ...
Posted by Michael Wonder on 14 Dec 2021
Health technology assessment: European Commission welcomes the adoption of new rules to improve access to innovative technologies
13 December 2021 - Today, the Regulation on Health Technology Assessment, a deliverable of the EU Pharmaceutical Strategy, has been adopted. ...
Posted by Michael Wonder on 14 Dec 2021
PHARMAC still stalled on lung cancer drug
14 December 2021 - Lung cancer sufferers are still waiting on PHARMAC to reverse a decision made more than a ...
Posted by Michael Wonder on 14 Dec 2021
FTC takes 'Pharma Bro' Martin Shkreli to trial over drug price hike
14 December 2021 - Shkreli is accused of masterminding an illegal scheme to jack up prices of the lifesaving drug Daraprim ...
Posted by Michael Wonder on 14 Dec 2021
TG Therapeutics announces FDA acceptance of biologics license application for ublituximab as a treatment for patients with relapsing forms of multiple sclerosis
14 December 2021 - Prescription Drug User Fee Act goal date of 28 September 2022. ...
Posted by Michael Wonder on 14 Dec 2021
EU regulation passed: G-BA works on European HTA assessment
14 December 2021 - Today the EU Parliament passed the EU-HTA regulation for a joint health technology assessment, which includes, ...
Posted by Michael Wonder on 14 Dec 2021
Trastuzumab deruxtecan supplemental new drug application submitted in Japan for treatment of patients with HER2 positive metastatic breast cancer
14 December 2021 - Submission based on groundbreaking DESTINY-Breast03 phase 3 trial, in which trastuzumab deruxtecan demonstrated a 72% reduction in ...
Posted by Michael Wonder on 14 Dec 2021
SMC approves first immunotherapy combination for advanced bowel cancer patients with rare mutation
14 December 2021 - Nivolumab plus ipilmumab has been accepted as a treatment option for adult patients by NHS Scotland ...
Posted by Michael Wonder on 14 Dec 2021
EMA reviewing new data on effectiveness of Lagevrio (molnupiravir) for the treatment of COVID-19
14 December 2021 - Following EMA’s interim recommendations to support national authorities who may decide on early use of Lagevrio ...
Posted by Michael Wonder on 14 Dec 2021
Private health pushes back on rates rise queries from Greg Hunt
14 December 2021 - Private health insurers are pushing back at Morrison government calls to reconsider a rise in their ...
Posted by Michael Wonder on 14 Dec 2021
FDA publishes discussion paper and seeks public input on 3D printing of medical devices at the point of care
10 December 2021 - Today, the U.S. FDA published a discussion paper regarding 3D printing medical devices at the point of ...
Posted by Michael Wonder on 14 Dec 2021
Permanent telehealth to strengthen universal Medicare
13 December 2021 - The Australian Government is investing $308.6 million to strengthen Australia’s primary care health system, building on our ...
Posted by Michael Wonder on 14 Dec 2021
Access Consortium statement on COVID-19 medicines
14 December 2021 - Vaccines have played a critical role in fighting the COVID-19 pandemic. However, medicines can still play ...
Posted by Michael Wonder on 14 Dec 2021
Australia launches National Preventive Health Strategy
13 December 2021 - The Australian Government has today launched the National Preventive Health Strategy, a 10 year plan to improve ...
Posted by Michael Wonder on 14 Dec 2021
New hope offered to rare disease patients
14 December 2021 - Early this month, the world's first therapy to treat spinal muscular atrophy, a rare genetic disorder ...